5-alpha Reductase Inhibitors/administration & dosage/*adverse effects Alopecia/drug therapy Depression/*chemically induced/epidemiology Finasteride/administration & dosage/*adverse effects Humans Male Prostatic Hyperplasia/drug therapy Sexual Dysfunction Physiological/chemically induced/epidemiology Suicidal Ideation

5-alpha Reductase Inhibitors Androgen Antagonists Humans Male Plant Extracts/*pharmacology *Prostatic Hyperplasia/drug therapy Randomized Controlled Trials as Topic *Serenoa/chemistry Tamsulosin

5-alpha Reductase Inhibitors Humans Male Oxidoreductases Prospective Studies *Prostatic Hyperplasia/drug therapy *Prostatic Neoplasms/drug therapy 5?-reductase inhibitors Bph Prostate cancer cancer specific mortality meta-analysis

5-alpha Reductase Inhibitors Adrenergic alpha-Antagonists Age Factors Humans Male Prostatic Hyperplasia/complications/physiopathology Time Factors Treatment Failure Treatment Outcome Urinary Bladder Underactive/complications/*physiopathology Urinary Retention/etiology/*physiopathology Benign prostatic enlargement Benign prostatic hyperplasia Bladder outlet obstruction Delayed prostatectomy Lower urinary tract symptoms

5-alpha Reductase Inhibitors/*administration & dosage Adrenergic alpha-1 Receptor Antagonists/*administration & dosage Drug Therapy Combination Dutasteride/*administration & dosage Erectile Dysfunction/chemically induced/diagnosis Humans Male Prostatic Hyperplasia/diagnosis/*drug therapy/epidemiology Randomized Controlled Trials as Topic/methods Tamsulosin/*administration & dosage Treatment Outcome Benign prostatic hyperplasia Dutasteride Meta-analysis Randomized controlled trials Tamsulosin published studies thus no ethical approval and patient consent are required. CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

5-alpha Reductase Inhibitors/pharmacology Blood Loss Surgical/*prevention & control Blood Transfusion Dutasteride/*pharmacology Hemoglobins/analysis Humans Male Microcirculation Prospective Studies Prostate Prostatic Hyperplasia Randomized Controlled Trials as Topic Retrospective Studies *Transurethral Resection of Prostate Treatment Outcome Vascular Endothelial Growth Factor A/metabolism Benign prostatic hyperplasia Dutasteride Intraoperative blood loss Meta-analysis Transurethral resection of the prostate

5-alpha Reductase Inhibitors/*adverse effects Drug Therapy Combination Ejaculation/drug effects Erectile Dysfunction/*chemically induced/drug therapy Finasteride Humans Libido/*drug effects Male Middle Aged Prostatic Hyperplasia/*drug therapy Randomized Controlled Trials as Topic *5α-Reductase Inhibitors *Erectile Dysfunction *Meta-Analysis *Sexual Dysfunction

5-alpha reductase inhibitors alpha-blockers BPH meta-analysis

5-alpha Reductase Inhibitors/therapeutic use Androgen Antagonists/therapeutic use Androgens/therapeutic use *Carcinoma in Situ Humans Male *Prostatic Neoplasms/pathology *Urinary Bladder Neoplasms/pathology *Androgen suppression therapy *Androgens *Bladder cancer *Incidence *Recurrence *Systematic review